Major adverse noncardiac events after PCI as predictors of long-term mortality

Journal of Interventional Cardiology

Volumn 21, Issue 5, 2008, Pages 395-402

  Harjai, Kishore ^a   Shenoy, Chetan ^a   Raizada, Amol ^a   Eswaran, Manivel ^a   Acharji, Subasit ^a   Sattur, Sudhakar ^a   Orshaw, Pamela ^a   Devarakonda, Srinivas ^a  

^a GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; HIRULOG;

ADULT; AGED; AORTA BALLOON; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RESTENOSIS; REVASCULARIZATION; STROKE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PENNSYLVANIA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 52749095682     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2008.00387.x     Document Type: Article

References (29)

1. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003 92:930 935.
2. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004 93:1092 1096.
3. O'Neill WW. Risk of bleeding after elective percutaneous coronary intervention. N Engl J Med 2006 355:1058 1060.
4. Rao SV, Kaul PR, Liao L, et al. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2008 155:369 374.
5. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997 103:368 375.
6. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002 105:2259 2264.
7. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003 108:2769 2775.
8. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004 93:1515 1519.
9. Hill ME, Rosenwaike I. The Social Security Administration's Death Master File: The completeness of death reporting at older ages. Soc Secur Bull 2001 64:45 51.
10. Harjai KJ, Raizada A, Shenoy C, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol 2008 101:812 819.
11. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987 76:142 154.
12. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents 5. N Engl J Med 2007 356:1020 1029.
13. Dauerman HL. Percutaneous coronary intervention pharmacology: From a triangle to a square. J Am Coll Cardiol 2008 51:698 700.
14. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004 351:1285 1295.
15. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002 143:847 853.
16. Rao SV, O'Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006 47:809 816.
17. Roe MT, Mahaffey KW, Kilaru R, et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J 2004 25:313 321.
18. Javaid A, Buch AN, Steinberg DH, et al. Does creatine kinase-MB (CK-MB) isoenzyme elevation following percutaneous coronary intervention with drug-eluting stents impact late clinical outcome Catheter Cardiovasc Interv 2007 70:826 831.
19. Halkin A, Stone GW, Grines CL, et al. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2006 47:951 961.
20. Blankenship JC, Haldis T, Feit F, et al. Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). Am J Cardiol 2006 97:1591 1596.
21. Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002 40:1961 1967.
22. Cai Q, Skelding KA, Armstrong AT Jr., et al. Predictors of periprocedural creatine kinase-myocardial band elevation complicating elective percutaneous coronary intervention. Am J Cardiol 2007 99:616 620.
23. Moore RK, Lowe R, Grayson AD, et al. A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention Int J Cardiol 2007 116:93 97.
24. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 355:2203 2216.
25. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004 292:696 703.
26. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008 51:690 697.
27. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007 50:e1 e157.
28. Hernandez AV, Westerhout CM, Steyerberg EW, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: Benefit and harm in different age subgroups. Heart 2007 93:450 455.
29. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993 329:673 682.